{"id":3689,"date":"2018-11-29T12:01:05","date_gmt":"2018-11-29T06:31:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3689"},"modified":"2021-07-24T12:57:08","modified_gmt":"2021-07-24T07:27:08","slug":"thebusinesscocktail47","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47","title":{"rendered":"Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Prometic bags USD 50 Million stock sale option to ease a cash crunch<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Prometic Life Sciences<\/strong> got into an\u00a0agreement\u00a0for selling <strong>USD 50 million<\/strong> in stock. This gives Prometic a way to escape its current financial pressures. <strong>Canada-based Prometic<\/strong> was asked by the <strong>FDA<\/strong> to make and validate process changes for <strong>Ryplazim<\/strong>, a <a href=\"https:\/\/www.delveinsight.com\/report-store\/congenital-heart-disease-pipeline-insight\">congenital<\/a> plasminogen deficiency treatment. The company reverted by contemplating to extend its financial runway, both by cutting costs and getting money into the business. The\u00a0<strong>R&amp;D<\/strong> costs are expected to plunge by USD 30 million in 2019.<\/p>\n<p style=\"text-align: justify;\"><strong>Vedanta receives USD 12 Million from Johnson &amp; Johnson for the microbiome drug trial<\/strong><\/p>\n<p style=\"text-align: justify;\">The collaboration of <strong>Vedanta Biosciences with Johnson &amp; Johnson<\/strong> on <strong>microbiome<\/strong> therapies has gone for the clinical stage, remunerating a <strong>USD 12 million<\/strong> payment. The volunteers are now being treated in a <strong>phase 1 trial<\/strong> of <strong>VE202<\/strong>, a bacteria-based treatment for <strong>inflammatory <a href=\"https:\/\/www.delveinsight.com\/report-store\/short-bowel-syndrome-market\">bowel <\/a>disease (IBD),<\/strong> focused on the microbiome &#8211; the population of gut bacteria that when out of balance are thought to play a role in many diseases.<\/p>\n<p style=\"text-align: justify;\"><strong>Humira biosimilar agreement to save more than USD 300 Million <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NHS England, the national health service,<\/strong> negotiated deals with five drugmakers to receive access to lower-cost versions of <strong>Humira<\/strong> of <strong>AbbVie<\/strong>. The health service apprised about <strong>USD 383 million<\/strong> in anticipated savings that it would be the biggest in NHS history from a single drug negotiation. The deals will decrease hospitals&#8217; Humira bills by around three-quarters and could pay for 11,700 more community nurses or 19,800 more breast cancer treatments for patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a congenital plasminogen deficiency [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3693,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,2247,704,900,2251,341,836,2252,2246,702,2248,2253,2250,2249],"industry":[17225],"therapeutic_areas":[17239,17278],"class_list":["post-3689","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-canada-based-prometic","tag-fda","tag-humira","tag-inflammatory-bowel-disease-ibd","tag-johnson-johnson","tag-microbiome","tag-nhs-england","tag-prometic-life-sciences","tag-rd","tag-ryplazim","tag-the-national-health-service","tag-ve202","tag-vedanta-biosciences","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Prometic raises $50M; Vedanta bags $12M; NHS saves \u00a3300m on Humira<\/title>\n<meta name=\"description\" content=\"Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prometic raises $50M; Vedanta bags $12M; NHS saves \u00a3300m on Humira\" \/>\n<meta property=\"og:description\" content=\"Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-29T06:31:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1992\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prometic raises $50M; Vedanta bags $12M; NHS saves \u00a3300m on Humira","description":"Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47","og_locale":"en_US","og_type":"article","og_title":"Prometic raises $50M; Vedanta bags $12M; NHS saves \u00a3300m on Humira","og_description":"Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures.....","og_url":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-29T06:31:05+00:00","article_modified_time":"2021-07-24T07:27:08+00:00","og_image":[{"width":3000,"height":1992,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47","url":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47","name":"Prometic raises $50M; Vedanta bags $12M; NHS saves \u00a3300m on Humira","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","datePublished":"2018-11-29T06:31:05+00:00","dateModified":"2021-07-24T07:27:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Prometic Life Sciences got into an\u00a0agreement\u00a0for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/thebusinesscocktail47#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1.jpg","width":"3000","height":"1992","caption":"vedanta"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020519\/HCGHR-2.2-Image1-300x199.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Canada-based Prometic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Humira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">inflammatory bowel disease (IBD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">microbiome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NHS England<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prometic Life Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">R&amp;D<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ryplazim<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">the national health service<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">VE202&#039;<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vedanta Biosciences<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Canada-based Prometic<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Humira<\/span>","<span class=\"advgb-post-tax-term\">inflammatory bowel disease (IBD)<\/span>","<span class=\"advgb-post-tax-term\">Johnson &amp; Johnson<\/span>","<span class=\"advgb-post-tax-term\">microbiome<\/span>","<span class=\"advgb-post-tax-term\">NHS England<\/span>","<span class=\"advgb-post-tax-term\">Prometic Life Sciences<\/span>","<span class=\"advgb-post-tax-term\">R&amp;D<\/span>","<span class=\"advgb-post-tax-term\">Ryplazim<\/span>","<span class=\"advgb-post-tax-term\">the national health service<\/span>","<span class=\"advgb-post-tax-term\">VE202&#039;<\/span>","<span class=\"advgb-post-tax-term\">Vedanta Biosciences<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 29, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 29, 2018 12:01 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3689"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3689\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3693"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3689"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3689"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}